Application Area — Cardiac Diagnostics
Skip the Screening. Start Building.
Every cardiac antibody pair is pre-validated on the platform you actually use — LFA, CLIA or ELISA. Go from catalog to assay in days, not months.
Cardiac biomarkers are proteins, enzymes and other molecules released into the bloodstream when cardiac tissue is damaged or under stress. In IVD diagnostics, they serve as measurable indicators for conditions including acute myocardial infarction (AMI), heart failure, preeclampsia and inflammatory states that affect cardiovascular function.
The most clinically important cardiac biomarkers in point-of-care and laboratory testing are cardiac Troponin I (cTnI) and Troponin T — the gold standard for AMI diagnosis — along with D-Dimer for thrombosis risk, CK-MB for early reinfarction detection, BNP/NT-proBNP for heart failure staging, and CRP and PCT for cardiac inflammation and sepsis stratification.
For IVD manufacturers, the antibody pair — a matched capture and detection antibody set — is the most critical reagent component. Its epitope specificity, cross-reactivity profile, and platform compatibility directly determine assay sensitivity, specificity and lot-to-lot reproducibility. Sekbio supplies pre-validated, production-grade antibody pairs across all major cardiac biomarker targets.
One Validation. Consistent Performance. Every Batch.
Sekbio cardiac antibodies are manufactured at industrial scale with tight lot-to-lot CV and full ISO 13485-certified traceability. Validate once, produce with confidence.
All products are available as matched antibody pairs (capture + detection), individual clones or colloidal gold conjugates. Click any product for full specifications.
| Biomarker | Clinical Use | Formats | Key Specs | Details |
|---|---|---|---|---|
| Cardiac Troponin I (cTnI) | AMI diagnosis, rule-in/rule-out | CLIALFAFIA | LoD <0.01 ng/mL; no skeletal TnI cross-reaction | View → |
| D-Dimer | DVT, PE exclusion, coagulation | LFACLIAELISA | Paired mAbs; fibrin-specific; low interference | View → |
| CK-MB | Early AMI, re-infarction detection | LFACLIAELISA | No CK-MM or CK-BB cross-reactivity | View → |
| Procalcitonin (PCT) | Sepsis diagnosis, antibiotic stewardship | LFACLIAFIA | Detects intact PCT; LoD <0.05 ng/mL | View → |
| C-Reactive Protein (CRP) | Inflammation, cardiovascular risk | LFACLIAELISA | Wide dynamic range; high-sensitivity CRP available | View → |
| H-FABP | Early AMI (<3 h onset), rule-out | LFAELISA | Rises within 1–3 h of injury; cardiac-specific | View → |
| Troponin T | AMI, chronic heart disease monitoring | CLIAELISA | Cardiac-specific isoform; complementary to cTnI | View → |
| PlGF / sFlt-1 | Preeclampsia prediction and monitoring | CLIAELISA | Paired PlGF + sFlt-1 ratio assay components | View → |
| Erythropoietin (EPO) | Anemia, CKD, cardiac load assessment | CLIAELISA | High sensitivity; broad linear range | View → |
| Ferritin | Iron deficiency, cardiac inflammation | LFACLIAELISA | Stable across wide concentration range; low HOOK effect | View → |
| Myoglobin (MYO) | Early AMI rule-out; rises within 1–4 h of onset | LFACLIAELISA | GSA501 (capture) + GSA503 (detection); validated vs Roche ECLIA; earliest-rising cardiac marker | View → |
| NT-proBNP | Heart failure diagnosis, NYHA staging and monitoring | LFACLIAELISA | 7 mouse mAbs + humanized variants; epitopes 13–76; HAMA-resistant humanized pair available | View → |
Sekbio cardiac antibody pairs are pre-validated and optimized for four IVD assay platforms. Each pair ships with platform-specific recommended working concentrations.
Colloidal gold and latex bead conjugates for rapid, instrument-free POC testing. Suitable for cTnI, D-Dimer, CRP, CK-MB, H-FABP and Ferritin.
Chemiluminescent immunoassay pairs for automated analyzer platforms. High-sensitivity formats available for cTnI, PCT and D-Dimer.
Sandwich ELISA-grade pairs for laboratory quantification. Biotin/streptavidin and HRP-conjugated detection antibodies available.
Fluorescent microsphere and time-resolved fluorescence conjugates for quantitative POC analyzers. Validated for cTnI and PCT.
Not sure which format is right for your assay? Sekbio's technical team can advise on antibody pair selection, conjugation chemistry and assay configuration based on your target LoD, matrix and instrument platform. Contact us or explore our antibody development services for custom pair screening.
The most common bottleneck in cardiac IVD development is antibody qualification — testing dozens of clone combinations across multiple platforms before finding a pair that meets sensitivity and specificity targets. Sekbio eliminates this step.
Every cardiac antibody pair is screened in a real sandwich immunoassay before catalog listing. You receive a pair that works on your target platform from day one.
Antibodies are produced in CHO or hybridoma bioreactors at batch sizes from 100 mg to gram scale, with full ISO 13485 documentation for regulatory submissions.
Lot-to-lot CV <10% on key performance parameters means your assay QC stays in control across production batches — no repeat validation cycles.
Our antibody scientists provide hands-on support for coating optimization, conjugation troubleshooting and cut-off calibration — included with every order.
Cardiac biomarker antibody pairs are matched sets of capture and detection antibodies used in sandwich immunoassays to quantify heart-related proteins in blood samples. They are the core reagent components in CLIA, lateral flow assay (LFA), ELISA and FIA diagnostic tests for conditions such as acute myocardial infarction, heart failure and preeclampsia.
Sekbio supplies antibody pairs for ten cardiac targets: Cardiac Troponin I (cTnI), D-Dimer, CK-MB, Procalcitonin (PCT), C-Reactive Protein (CRP), Heart-type Fatty Acid Binding Protein (H-FABP), Troponin T, PlGF/sFlt-1, Erythropoietin (EPO) and Ferritin. All pairs are pre-validated on at least one clinical assay platform before catalog release.
Yes. Every antibody pair in the Sekbio cardiac portfolio is pre-validated on the platform it is intended for — LFA, CLIA, ELISA or FIA — before being released to customers. Platform-specific data including signal-to-noise ratios, working concentration ranges and lot-to-lot CV values are available upon request alongside the product datasheet.
The standard MOQ is 1 mg per antibody clone, which is sufficient for initial assay feasibility studies. For scale-up and routine production, quantities from 10 mg to gram scale are available with full ISO 13485-certified batch documentation and Certificate of Analysis.
Each batch undergoes SEC-HPLC purity testing, SDS-PAGE, binding activity ELISA and platform-specific functional assays. Lot-to-lot CV for key performance parameters is maintained below 10%. All manufacturing is conducted under an ISO 13485-certified quality management system, and full traceability documentation is provided with every shipment.
Yes. If you require an antibody pair for a cardiac target not in our catalog, Sekbio offers end-to-end custom antibody development — from antigen design and immunization to hybridoma screening, pairing validation and stable cell line establishment. Delivery for a complete custom project is typically 8–12 weeks. Explore our antibody development platforms for details on the workflow and timelines.
Every shipment includes a Certificate of Analysis (CoA) with purity, activity and lot number; a Safety Data Sheet (SDS); and, upon request, full raw QC data including SEC-HPLC chromatograms and functional assay curves. All documentation is aligned with ISO 13485 traceability requirements for IVD regulatory submissions.
Request a sample, download datasheets, or speak with a Sekbio antibody scientist about your assay requirements.